The latest progress in research on triple negative breast cancer (TNBC): risk factors, possible therapeutic targets and prognostic markers

Triple negative breast cancer (TNBC) is one type of breast cancer (BC), which is defined as negative for estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor-2 (Her2). Its origins and development seem to be elusive. And for now, drugs like tamoxifen or trastu...

Full description

Saved in:
Bibliographic Details
Published inJournal of thoracic disease Vol. 6; no. 9; pp. 1329 - 1335
Main Authors Jiao, Qingli, Wu, Aiguo, Shao, Guoli, Peng, Haoyu, Wang, Mengchuan, Ji, Shufeng, Liu, Peng, Zhang, Jian
Format Journal Article
LanguageEnglish
Published China Pioneer Bioscience Publishing Company 01.09.2014
Subjects
Review
prognostic marker
therapeutic target
Triple negative breast cancer (TNBC)
risk factor
Online AccessGet full text

Cover

More Information
Summary:Triple negative breast cancer (TNBC) is one type of breast cancer (BC), which is defined as negative for estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor-2 (Her2). Its origins and development seem to be elusive. And for now, drugs like tamoxifen or trastuzumab which specifically apply to ER, PR or Her2 positive BC seem unforeseeable in TNBC clinical treatment. Due to its extreme malignancy, high recurrence rate and poor prognosis, a lot of work on the research of TNBC is needed. This review aims to summarize the latest findings in TNBC in risk factors, possible therapeutic targets and possible prognostic makers.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:2072-1439
2077-6624
DOI:10.3978/j.issn.2072-1439.2014.08.13